CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Isotretinoin prior authorization and coverage

Policy governs prior authorization and coverage criteria for isotretinoin for Medicaid members of Neighborhood Health Plan of Rhode Island, including approved diagnoses and treatment limits.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyIsotretinoin prior authorization and coverage

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 1, 2019

Next Review DateN/A

Key ActionObtain prior authorization and document diagnosis plus prior inadequate trials of a topical acne product and an oral antibiotic when applicable.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsauthorized coverage period

40 weeksmax treatment duration

≥8 weeksmin interval between courses

2019-01 / through 2026-04effective / reviewed

Coverage Criteria for Isotretinoin

Initial coverage criteria

Covered when ALL of the following are met:

Primary diagnostic and prior-treatment criteria: Patient has one of: A) severe recalcitrant nodular acne vulgaris, B) refractory acne vulgaris, OR C) severe refractory rosacea; AND patient has tried and had inadequate treatment responses to any topical acne product AND an oral antibiotic.

Coverage limited to 12 months with prior authorization; treatment limited to 40 weeks (≤2 courses) with ≥8 weeks between courses.

Alternative covered diagnoses without prior topical/antibiotic requirement: Patient has one of: Transient acantholytic dermatosis (Grover's Disease), Keratosis follicularis (Darier Disease), Lamellar ichthyosis, OR Pityriasis rubra pilaris.

These diagnoses are listed as covered indications; prior topical and oral antibiotic trial requirement is not restated for these conditions in the document.

Isotretinoin is contraindicated in pregnancy because it is teratogenic. The FDA‑approved labeling specifies that isotretinoin is indicated only for female patients who are not pregnant due to the risk of severe birth defects; prescribers should ensure pregnancy is excluded before initiation and manage accordingly.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyIsotretinoin prior authorization and coverage

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 1, 2019

Next Review DateN/A

Key ActionObtain prior authorization and document diagnosis plus prior inadequate trials of a topical acne product and an oral antibiotic when applicable.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Provider Actions and Authorization Requirements

Prior Authorization

Prior Authorization Required

Isotretinoin requires prior authorization for up to 12 months. Coverage is allowed when diagnostic and prior-treatment criteria are met.

Prior authorization required for up to 12 months
Treatment limited to 40 weeks (two courses) or less with at least 8 weeks between courses

Step Therapy

Provider-required Trials

For acne or rosacea diagnoses, the patient must have tried and had inadequate responses to both: 1) a topical acne product, AND 2) an oral antibiotic before approval.

Applies to diagnoses: severe recalcitrant nodular acne vulgaris; refractory acne vulgaris; severe refractory rosacea

Documentation Required

Documentation Requirements

Documentation must support the patients diagnosis and prior inadequate response to the required topical and oral antibiotic trials. Include dates, agents tried, duration of therapy, and reason for failure or intolerance.

Support diagnosis with clinical notes
Document topical product trial (agent, dates, response)
Document oral antibiotic trial (agent, dates, response)

Denial Risk

Denial Conditions

Requests that do not meet the coverage criteria will be denied. Denial reasons include: unsupported diagnosis, missing documentation of inadequate topical and oral antibiotic trials, exceeding duration limits, or use for non-covered indications.

Denial if criteria (diagnosis, prior trials, duration limits, or documentation) not met
Not covered for indications outside the listed diagnoses

Background and Indications

Isotretinoin is indicated for severe recalcitrant nodular acne and several severe or refractory dermatologic conditions. The label defines nodules as inflammatory lesions ≥5 mm in diameter that may become suppurative or hemorrhagic, and reserves isotretinoin for patients unresponsive to conventional therapy including systemic antibiotics.

A single course of therapy is typically 15–20 weeks and often results in prolonged remission. If retreatment is needed, a second course should not begin until at least 8 weeks after completion of the first course. Under the coverage policy, treatment is limited to 40 weeks (≤2 courses) with a minimum interval of ≥8 weeks between courses, and prior authorization is required for coverage up to 12 months.

Definitions

inv-08: Definition — Nodules

DefinitionNodules are inflammatory lesions with a diameter of 5 mm or greater; they may become suppurative or hemorrhagic.

Clinical relevanceNodules are the lesion type that defines severe recalcitrant nodular acne — the primary FDA‑approved indication for isotretinoin.

Measurement thresholdDiameter ≥ 5 mm distinguishes nodules from smaller inflammatory lesions.

inv-09: Definition — 'Severe' nodular acne

Definition of 'Severe''Severe' denotes 'many' nodules (as opposed to 'few' or 'several').

Treatment indication'Severe' nodular acne is the condition for which isotretinoin is indicated when patients are unresponsive to conventional therapy, including systemic antibiotics.

Use restrictionIsotretinoin should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy due to significant adverse effects.

Revision History

2019-01-01effective

Policy effective date

2019-02review

Policy reviewed

2020-02review

Policy reviewed

2021-06review

Policy reviewed

2022-04review

Policy reviewed

2023-04review

Policy reviewed

2024-05review

Policy reviewed

2025-05review

Policy reviewed

2026-04reviewLatest

Policy reviewed through April 2026